Macquarie Group’s Neuropace NPCE Stock Holding History

Macquarie Group’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,198	Closed	-$16	–	2056
2024 Q1	$16	Buy	+1,198	New	+$17.1K	﹤0.01%	1704

Other funds holding NPCE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

KLC

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's NPCE Position: Q2 2024 in Review

Macquarie Group sold out of Neuropace (NPCE) in Q2 2024, closing a stake of 1,198 shares — an estimated $16 sold.

Macquarie Group first reported a position in NPCE in Q1 2024 and held it in 1 quarter. The position peaked at $16 in Q1 2024. 51 funds tracked by Wall St. Rank hold NPCE as of Q2 2024.

Macquarie Group reported no remaining Neuropace position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 1,198 Neuropace shares in Q2 2024, an estimated $16.
Macquarie Group first reported a position in Neuropace in Q1 2024 and held it in 1 quarter.
Macquarie Group's Neuropace position peaked at $16 in Q1 2024.
51 funds tracked by Wall St. Rank held Neuropace as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.